

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:sssptal646jxs

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * Welcome to STN International * * * * *

NEWS 1 Web Page URLs for STN Seminar Schedule - N. America
NEWS 2 "Ask CAS" for self-help around the clock
NEWS 3 SEP 09 CA/CAPLUS records now contain indexing from 1907 to the
present
NEWS 4 AUG 05 New pricing for EUROPATFULL and PCTFULL effective
August 1, 2003
NEWS 5 AUG 13 Field Availability (/FA) field enhanced in BEILSTEIN
NEWS 6 AUG 18 Data available for download as a PDF in RDISCLOSURE
NEWS 7 AUG 18 Simultaneous left and right truncation added to PASCAL
NEWS 8 AUG 18 FROSTI and KOSMET enhanced with Simultaneous Left and Right
Truncation
NEWS 9 AUG 18 Simultaneous left and right truncation added to ANABSTR
NEWS 10 SEP 22 DIPPR file reloaded
NEWS 11 SEP 25 INPADOC: Legal Status data to be reloaded
NEWS 12 SEP 29 DISSABS now available on STN
NEWS 13 OCT 10 PCTFULL: Two new display fields added

NEWS EXPRESS OCTOBER 01 CURRENT WINDOWS VERSION IS V6.01a, CURRENT
MACINTOSH VERSION IS V6.0b(ENG) AND V6.0Jb(JP),
AND CURRENT DISCOVER FILE IS DATED 23 SEPTEMBER 2003
NEWS HOURS STN Operating Hours Plus Help Desk Availability
NEWS INTER General Internet Information
NEWS LOGIN Welcome Banner and News Items
NEWS PHONE Direct Dial and Telecommunication Network Access to STN
NEWS WWW CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that
specific topic.

All use of STN is subject to the provisions of the STN Customer
agreement. Please note that this agreement limits use to scientific
research. Use for software development or design or implementation
of commercial gateways or other similar uses is prohibited and may
result in loss of user privileges and other penalties.

* * * * * STN Columbus * * * * *

FILE 'HOME' ENTERED AT 17:17:12 ON 16 OCT 2003

=> file medline caplus embase biosis cancerlit uspatful		
COST IN U.S. DOLLARS	SINCE FILE	TOTAL
	ENTRY	SESSION
FULL ESTIMATED COST	0.42	0.42

FILE 'MEDLINE' ENTERED AT 17:18:10 ON 16 OCT 2003

FILE 'CAPLUS' ENTERED AT 17:18:10 ON 16 OCT 2003
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2003 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'EMBASE' ENTERED AT 17:18:10 ON 16 OCT 2003
COPYRIGHT (C) 2003 Elsevier Inc. All rights reserved.

FILE 'BIOSIS' ENTERED AT 17:18:10 ON 16 OCT 2003
COPYRIGHT (C) 2003 BIOLOGICAL ABSTRACTS INC.(R)

FILE 'CANCERLIT' ENTERED AT 17:18:10 ON 16 OCT 2003

FILE 'USPATFULL' ENTERED AT 17:18:10 ON 16 OCT 2003
CA INDEXING COPYRIGHT (C) 2003 AMERICAN CHEMICAL SOCIETY (ACS)

=> s modulat? (w) angiogenesis
L1 700 MODULAT? (W) ANGIOGENESIS

=> s zinc (w) finger (w) protein
L2 13117 ZINC (W) FINGER (W) PROTEIN

=> s l1 (s) l2
L3 3 L1 (S) L2

=> d l3 1- ibib,abs
YOU HAVE REQUESTED DATA FROM 3 ANSWERS - CONTINUE? Y/(N):y

L3 ANSWER 1 OF 3 USPATFULL on STN

ACCESSION NUMBER: 2003:200905 USPATFULL

TITLE: Novel G protein-coupled receptor family members, human
thioredoxin family members, human leucine-rich repeat
family members, and human ringfinger family member
INVENTOR(S): Glucksmann, Maria Alexandra, Lexington, MA, UNITED
STATES

Silos-Santiago, Inmaculada, Jamaica Plain, MA, UNITED
STATES
Galvin, Katherine M., Jamaica Plain, MA, UNITED STATES
Weich, Nadine, Brookline, MA, UNITED STATES
Curtis, Rory A. J., Framingham, MA, UNITED STATES
Bandaru, Rajasekhar, Watertown, MA, UNITED STATES
Kapeller-Libermann, Rosana, Chestnut Hill, MA, UNITED
STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003138890	A1	20030724
APPLICATION INFO.:	US 2002-145586	A1	20020514 (10)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 2001-796338, filed on 28 Feb 2001, PENDING Continuation-in-part of Ser. No. WO 2001-US6543, filed on 28 Feb 2001, PENDING		

	NUMBER	DATE
PRIORITY INFORMATION:	WO 2001-US6057	20010223
	WO 2001-US23152	20010723
	WO 2001-US40476	20010409
	WO 2001-US7139	20010305
	WO 2001-US19544	20010615
	WO 2001-US29967	20010925
	WO 2001-US9470	20010323
	WO 2001-US10380	20010330
	WO 2001-US29968	20010925
	US 2000-186059P	20000229 (60)
	US 2000-220042P	20000721 (60)
	US 2000-187447P	20000307 (60)
	US 2000-211673P	20000615 (60)
	US 2000-235049P	20000925 (60)

US 2000-191863P 20000324 (60)
US 2000-193919P 20000331 (60)
US 2000-235032P 20000925 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: JOHN W. FREEMAN, ESQ., Fish & Richardson P.C., 225
Franklin Street, Boston, MA, 02110-2804
NUMBER OF CLAIMS: 19
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 97 Drawing Page(s)
LINE COUNT: 51652

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention provides isolated nucleic acids molecules, designated 20716, 65494, 44576, 1983, 52881, 2398, 45449, 50289, 52872, 22105, 22109, 22108, 47916, 33395, 31939, and 84241 nucleic acid molecules, which encode novel G protein-coupled receptor family members, human thioredoxin family members, human leucine-rich repeat family members, and human ringfinger family member. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing 20716, 65494, 44576, 1983, 52881, 2398, 45449, 50289, 52872, 22105, 22109, 22108, 47916, 33395, 31939, or 84241 nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a 20716, 65494, 44576, 1983, 52881, 2398, 45449, 50289, 52872, 22105, 22109, 22108, 47916, 33395, 31939, or 84241 gene has been introduced or disrupted. The invention still further provides isolated 20716, 65494, 44576, 1983, 52881, 2398, 45449, 50289, 52872, 22105, 22109, 22108, 47916, 33395, 31939, or 84241 proteins, fusion proteins, antigenic peptides and anti-20716, 65494, 44576, 1983, 52881, 2398, 45449, 50289, 52872, 22105, 22109, 22108, 47916, 33395, 31939, or 84241 antibodies. Diagnostic methods utilizing compositions of the invention are also provided.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 2 OF 3 USPATFULL on STN

ACCESSION NUMBER: 2003:64284 USPATFULL
TITLE: Regulation of angiogenesis with zinc finger proteins
INVENTOR(S): Rebar, Edward, El Cerrito, CA, UNITED STATES
Jamieson, Andrew, San Francisco, CA, UNITED STATES
Liu, Qiang, Foster City, CA, UNITED STATES
Liu, Pei-Qi, Richmond, CA, UNITED STATES
Wolffe, Alan, Orinda, CA, UNITED STATES
Eisenberg, Stephen P., Boulder, CO, UNITED STATES
Jarvis, Eric, Boulder, CO, UNITED STATES

NUMBER KIND DATE

PATENT INFORMATION: US 2003044404 A1 20030306
APPLICATION INFO.: US 2001-846033 A1 20010430 (9)
RELATED APPLN. INFO.: Continuation-in-part of Ser. No. US 2000-736083, filed
on 12 Dec 2000, ABANDONED Continuation-in-part of Ser.
No. US 2000-733604, filed on 7 Dec 2000, ABANDONED

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: TOWNSEND AND TOWNSEND AND CREW, LLP, TWO EMBARCADERO
CENTER, EIGHTH FLOOR, SAN FRANCISCO, CA, 94111-3834
NUMBER OF CLAIMS: 95
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 26 Drawing Page(s)
LINE COUNT: 4997

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Provided herein are a variety of methods and compositions for regulating angiogenesis, such methods and compositions being useful in a variety of applications where modulation of vascular formation is useful, including, but not limited to, treatments for ischemia and wound

healing. Certain of the methods and compositions accomplish this by using various zinc finger proteins that bind to particular target sites in one or more VEGF genes. Nucleic acids encoding the zinc finger proteins are also disclosed. Methods for modulating the expression of one or more VEGF genes with the zinc finger proteins and nucleic acids are also disclosed. Such methods can also be utilized in a variety of therapeutic applications that involve the regulation of endothelial cell growth. Pharmaceutical compositions including the zinc finger proteins or nucleic acids encoding them are also provided.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 3 OF 3 USPATFULL on STN

ACCESSION NUMBER: 2003:29834 USPATFULL
 TITLE: Regulation of angiogenesis with zinc finger proteins
 INVENTOR(S): Rebar, Edward, El Cerrito, CA, UNITED STATES
 Jamieson, Andrew, San Francisco, CA, UNITED STATES
 Liu, Qiang, Foster City, CA, UNITED STATES
 Liu, Pei-Qi, Richmond, CA, UNITED STATES
 Wolffe, Alan, Orinda, CA, UNITED STATES
 Eisenberg, Stephen P., Boulder, CO, UNITED STATES
 Jarvis, Eric, Boulder, CO, UNITED STATES
 PATENT ASSIGNEE(S): Sangamo BioSciences, Inc., Richmond, CA, UNITED STATES
 (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003021776	A1	20030130
APPLICATION INFO.:	US 2001-6069	A1	20011206 (10)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 2001-846033, filed on 30 Apr 2001, PENDING Continuation-in-part of Ser. No. US 2000-736083, filed on 12 Dec 2000, ABANDONED Continuation-in-part of Ser. No. US 2000-733604, filed on 7 Dec 2000, ABANDONED		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	APPLICATION		
LEGAL REPRESENTATIVE:	TOWNSEND AND TOWNSEND AND CREW, LLP, TWO EMBARCADERO CENTER, EIGHTH FLOOR, SAN FRANCISCO, CA, 94111-3834		
NUMBER OF CLAIMS:	98		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	27 Drawing Page(s)		
LINE COUNT:	5975		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Provided herein are a variety of methods and compositions for regulating angiogenesis, such methods and compositions being useful in a variety of applications where modulation of vascular formation is useful, including, but not limited to, treatments for ischemia and wound healing. Certain of the methods and compositions accomplish this by using various zinc finger proteins that bind to particular target sites in one or more VEGF genes. Nucleic acids encoding the zinc finger proteins are also disclosed. Methods for modulating the expression of one or more VEGF genes with the zinc finger proteins and nucleic acids are also disclosed. Such methods can also be utilized in a variety of therapeutic applications that involve the regulation of endothelial cell growth. Pharmaceutical compositions including the zinc finger proteins or nucleic acids encoding them are also provided.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

=>

=> s 11 (p) 12
 L4 3 L1 (P) L2

=> s l1 and l2

L5 9 L1 AND L2

=> duplicate remove l5

PROCESSING COMPLETED FOR L5

L6 9 DUPLICATE REMOVE L5 (0 DUPLICATES REMOVED)

=> d l6 1- ibib,abs

YOU HAVE REQUESTED DATA FROM 9 ANSWERS - CONTINUE? Y/(N):y

L6 ANSWER 1 OF 9 USPATFULL on STN

ACCESSION NUMBER: 2003:213696 USPATFULL

TITLE: Differentially-expressed genes and polypeptides in angiogenesis

INVENTOR(S): Sun, Zairen, Rockville, MD, UNITED STATES

Jay, Gilbert, North Bethesda, MD, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003148334	A1	20030807
APPLICATION INFO.:	US 2002-268994	A1	20021011 (10)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2001-328395P	20011012 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	ORIGENE TECHNOLOGIES, INCORPORATED, 6 TAFT COURT, SUITE 100, ROCKVILLE, MD, 20850	
NUMBER OF CLAIMS:	18	
EXEMPLARY CLAIM:	1	
LINE COUNT:	3196	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention relates to all facets of polynucleotides, the polypeptides they encode, antibodies and specific binding partners thereto, and their applications to research, diagnosis, drug discovery, therapy, clinical medicine, forensic science and medicine, etc. The polynucleotides are expressed during angiogenesis and are therefore useful in variety of ways, including, but not limited to, as molecular markers, as drug targets, and for detecting, diagnosing, staging, monitoring, prognosticating, preventing or treating, determining predisposition to, etc., diseases and conditions, such as abnormal, insufficient, excessive, etc., angiogenesis, such as inflammatory diseases, such as rheumatoid arthritis, osteoarthritis, asthma, pulmonary fibrosis, age-related macular degeneration (ARMD), diabetic retinopathy, macular degeneration, and retinopathy of prematurity (ROP), endometriosis, cancer, Coats' disease, peripheral retinal neovascularization, neovascular glaucoma, psoriasis, retrolental fibroplasias, angiofibroma, inflammation, etc

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 2 OF 9 USPATFULL on STN

ACCESSION NUMBER: 2003:200905 USPATFULL

TITLE: Novel G protein-coupled receptor family members, human thioredoxin family members, human leucine-rich repeat family members, and human ringfinger family member

INVENTOR(S): Glucksmann, Maria Alexandra, Lexington, MA, UNITED STATES

Silos-Santiago, Inmaculada, Jamaica Plain, MA, UNITED STATES

Galvin, Katherine M., Jamaica Plain, MA, UNITED STATES

Weich, Nadine, Brookline, MA, UNITED STATES

Curtis, Rory A. J., Framingham, MA, UNITED STATES

Bandaru, Rajasekhar, Watertown, MA, UNITED STATES

Kapeller-Libermann, Rosana, Chestnut Hill, MA, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003138890	A1	20030724
APPLICATION INFO.:	US 2002-145586	A1	20020514 (10)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 2001-796338, filed on 28 Feb 2001, PENDING Continuation-in-part of Ser. No. WO 2001-US6543, filed on 28 Feb 2001, PENDING		

	NUMBER	DATE
PRIORITY INFORMATION:	WO 2001-US6057	20010223
	WO 2001-US23152	20010723
	WO 2001-US40476	20010409
	WO 2001-US7139	20010305
	WO 2001-US19544	20010615
	WO 2001-US29967	20010925
	WO 2001-US9470	20010323
	WO 2001-US10380	20010330
	WO 2001-US29968	20010925
	US 2000-186059P	20000229 (60)
	US 2000-220042P	20000721 (60)
	US 2000-187447P	20000307 (60)
	US 2000-211673P	20000615 (60)
	US 2000-235049P	20000925 (60)
	US 2000-191863P	20000324 (60)
	US 2000-193919P	20000331 (60)
	US 2000-235032P	20000925 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: JOHN W. FREEMAN, ESQ., Fish & Richardson P.C., 225 Franklin Street, Boston, MA, 02110-2804

NUMBER OF CLAIMS: 19
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 97 Drawing Page(s)
LINE COUNT: 51652

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention provides isolated nucleic acids molecules, designated 20716, 65494, 44576, 1983, 52881, 2398, 45449, 50289, 52872, 22105, 22109, 22108, 47916, 33395, 31939, and 84241 nucleic acid molecules, which encode novel G protein-coupled receptor family members, human thioredoxin family members, human leucine-rich repeat family members, and human ringfinger family member. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing 20716, 65494, 44576, 1983, 52881, 2398, 45449, 50289, 52872, 22105, 22109, 22108, 47916, 33395, 31939, or 84241 nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a 20716, 65494, 44576, 1983, 52881, 2398, 45449, 50289, 52872, 22105, 22109, 22108, 47916, 33395, 31939, or 84241 gene has been introduced or disrupted. The invention still further provides isolated 20716, 65494, 44576, 1983, 52881, 2398, 45449, 50289, 52872, 22105, 22109, 22108, 47916, 33395, 31939, or 84241 proteins, fusion proteins, antigenic peptides and anti-20716, 65494, 44576, 1983, 52881, 2398, 45449, 50289, 52872, 22105, 22109, 22108, 47916, 33395, 31939, or 84241 antibodies. Diagnostic methods utilizing compositions of the invention are also provided.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 3 OF 9 USPATFULL on STN
ACCESSION NUMBER: 2003:173872 USPATFULL
TITLE: Oligopeptide treatment of anthrax
INVENTOR(S): Khan, Nisar Ahmed, Rotterdam, NETHERLANDS

Benner, Robert, Barendrecht, NETHERLANDS

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003119720	A1	20030626
APPLICATION INFO.:	US 2001-29206	A1	20011221 (10)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 2001-821380, filed on 29 Mar 2001, PENDING		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	APPLICATION		
LEGAL REPRESENTATIVE:	TRASK BRITT, P.O. BOX 2550, SALT LAKE CITY, UT, 84110		
NUMBER OF CLAIMS:	16		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	39 Drawing Page(s)		
LINE COUNT:	3726		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention relates to the modulation of gene expression in a cell, also called gene control, in particular in relation to the treatment of anthrax. The invention provides a method for modulating expression of a gene in a cell comprising providing the cell with a signaling molecule comprising a peptide or functional analogue thereof.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 4 OF 9 USPATFULL on STN

ACCESSION NUMBER: 2003:165878 USPATFULL
TITLE: Gene regulator
INVENTOR(S): Khan, Nisar Asmed, Rotterdam, NETHERLANDS
Benner, Robert, Barendrecht, NETHERLANDS

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003113733	A1	20030619
APPLICATION INFO.:	US 2001-28075	A1	20011221 (10)

	NUMBER	DATE
PRIORITY INFORMATION:	EP 2001-203748	20011004
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	TRASK BRITT, P.O. BOX 2550, SALT LAKE CITY, UT, 84110	
NUMBER OF CLAIMS:	24	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	39 Drawing Page(s)	
LINE COUNT:	3699	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention relates to the modulation of gene expression in a cell, also called gene control, in particular in relation to the treatment of a variety of diseases. The invention provides a method for modulating expression of a gene in a cell comprising providing said cell with a signalling molecule comprising a peptide or functional analogue thereof. Furthermore, the invention provides a method for identifying or obtaining a signalling molecule comprising a peptide or functional derivative or analogue thereof capable of modulating expression of a gene in a cell comprising providing said cell with a peptide or derivative or analogue thereof and determining the activity and/or nuclear translocation of a gene transcription factor.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 5 OF 9 USPATFULL on STN

ACCESSION NUMBER: 2003:106910 USPATFULL
TITLE: Novel transcription factor-like protein and nucleic acids encoding same
INVENTOR(S): Carulli, John, Southborough, MA, UNITED STATES

Kotelianski, Victor, Boston, MA, UNITED STATES
de Fougierolles, Antonin, Brookline, MA, UNITED STATES
Green, Cynthia, Madison, CT, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003073823	A1	20030417
APPLICATION INFO.:	US 2001-809452	A1	20010315 (9)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-189799P	20000316 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	Ivor R. Elrifi, MINTZ, LEVIN, COHN, FERRIS,, GLOVSKY and POPEO, P.C., One Financial Center, Boston, MA, 02111	
NUMBER OF CLAIMS:	43	
EXEMPLARY CLAIM:	1	
LINE COUNT:	3521	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention provides novel isolated TF polynucleotides and polypeptides encoded by the TF polynucleotides. Also provided are the antibodies that immunospecifically bind to a TF polypeptide or any derivative, variant, mutant or fragment of the TF polypeptide, polynucleotide or antibody. The invention additionally provides methods in which the TF polypeptide, polynucleotide and antibody are utilized in the detection and treatment of a broad range of pathological states, as well as to other uses.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 6 OF 9 USPATFULL on STN
ACCESSION NUMBER: 2003:64284 USPATFULL
TITLE: Regulation of angiogenesis with **zinc finger proteins**
INVENTOR(S): Rebar, Edward, El Cerrito, CA, UNITED STATES
Jamieson, Andrew, San Francisco, CA, UNITED STATES
Liu, Qiang, Foster City, CA, UNITED STATES
Liu, Pei-Qi, Richmond, CA, UNITED STATES
Wolffe, Alan, Orinda, CA, UNITED STATES
Eisenberg, Stephen P., Boulder, CO, UNITED STATES
Jarvis, Eric, Boulder, CO, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003044404	A1	20030306
APPLICATION INFO.:	US 2001-846033	A1	20010430 (9)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 2000-736083, filed on 12 Dec 2000, ABANDONED Continuation-in-part of Ser. No. US 2000-733604, filed on 7 Dec 2000, ABANDONED		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	APPLICATION		
LEGAL REPRESENTATIVE:	TOWNSEND AND TOWNSEND AND CREW, LLP, TWO EMBARCADERO CENTER, EIGHTH FLOOR, SAN FRANCISCO, CA, 94111-3834		
NUMBER OF CLAIMS:	95		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	26 Drawing Page(s)		
LINE COUNT:	4997		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Provided herein are a variety of methods and compositions for regulating angiogenesis, such methods and compositions being useful in a variety of applications where modulation of vascular formation is useful, including, but not limited to, treatments for ischemia and wound healing. Certain of the methods and compositions accomplish this by

using various **zinc finger proteins** that bind to particular target sites in one or more VEGF genes. Nucleic acids encoding the **zinc finger proteins** are also disclosed. Methods for modulating the expression of one or more VEGF genes with the **zinc finger proteins** and nucleic acids are also disclosed. Such methods can also be utilized in a variety of therapeutic applications that involve the regulation of endothelial cell growth. Pharmaceutical compositions including the **zinc finger proteins** or nucleic acids encoding them are also provided.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 7 OF 9 USPATFULL on STN

ACCESSION NUMBER: 2003:37506 USPATFULL
TITLE: Regulator gene and system useful for the diagnosis and therapy of osteoporosis
INVENTOR(S): Warman, Matthew L., Shaker Heights, OH, UNITED STATES
Gong, Yaoqin, Jinan, CHINA
Olsen, Bjorn R., Milton, MA, UNITED STATES
Rawadi, Georges, Paris, FRANCE
Roman-Roman, Sergio, Paris, FRANCE

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003027151	A1	20030206
APPLICATION INFO.:	US 2001-931375	A1	20010817 (9)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2001-304851P	20010713 (60)
	US 2000-226119P	20000818 (60)
	US 2000-234337P	20000922 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	HELLER EHRMAN WHITE & MCAULIFFE LLP, 1666 K STREET,NW, SUITE 300, WASHINGTON, DC, 20006	
NUMBER OF CLAIMS:	36	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	16 Drawing Page(s)	
LINE COUNT:	3896	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB A bone strength and mineralization regulatory ("BSMR") protein is provided that can exist in multiple forms and that affects bone density. Polymorphic gene sequences of the protein are provided that are diagnostic of predisposition to osteoporosis. Other detection tools, compositions and methods of their use also are provided for predicting, evaluating and altering bone strength and mineralization status. The invention provides new natural and synthetic pharmaceuticals that effect the BSMR regulatory pathway and improve bone status. Tools also are provided for finding new pharmaceuticals that operate by binding to BSMR and that activate and/or deactivate this protein's biological function related to osteoporosis and blood vessel formation.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 8 OF 9 USPATFULL on STN

ACCESSION NUMBER: 2003:29834 USPATFULL
TITLE: Regulation of angiogenesis with **zinc finger proteins**
INVENTOR(S): Rebar, Edward, El Cerrito, CA, UNITED STATES
Jamieson, Andrew, San Francisco, CA, UNITED STATES
Liu, Qiang, Foster City, CA, UNITED STATES
Liu, Pei-Qi, Richmond, CA, UNITED STATES
Wolffe, Alan, Orinda, CA, UNITED STATES

Eisenberg, Stephen P., Boulder, CO, UNITED STATES
Jarvis, Eric, Boulder, CO, UNITED STATES
PATENT ASSIGNEE(S): Sangamo BioSciences, Inc., Richmond, CA, UNITED STATES
(U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003021776	A1	20030130
APPLICATION INFO.:	US 2001-6069	A1	20011206 (10)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 2001-846033, filed on 30 Apr 2001, PENDING Continuation-in-part of Ser. No. US 2000-736083, filed on 12 Dec 2000, ABANDONED Continuation-in-part of Ser. No. US 2000-733604, filed on 7 Dec 2000, ABANDONED		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	APPLICATION		
LEGAL REPRESENTATIVE:	TOWNSEND AND TOWNSEND AND CREW, LLP, TWO EMBARCADERO CENTER, EIGHTH FLOOR, SAN FRANCISCO, CA, 94111-3834		
NUMBER OF CLAIMS:	98		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	27 Drawing Page(s)		
LINE COUNT:	5975		
CAS INDEXING IS AVAILABLE FOR THIS PATENT.			

AB Provided herein are a variety of methods and compositions for regulating angiogenesis, such methods and compositions being useful in a variety of applications where modulation of vascular formation is useful, including, but not limited to, treatments for ischemia and wound healing. Certain of the methods and compositions accomplish this by using various **zinc finger proteins** that bind to particular target sites in one or more VEGF genes. Nucleic acids encoding the **zinc finger proteins** are also disclosed. Methods for modulating the expression of one or more VEGF genes with the **zinc finger proteins** and nucleic acids are also disclosed. Such methods can also be utilized in a variety of therapeutic applications that involve the regulation of endothelial cell growth. Pharmaceutical compositions including the **zinc finger proteins** or nucleic acids encoding them are also provided.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 9 OF 9 USPATFULL on STN
ACCESSION NUMBER: 2001:36951 USPATFULL
TITLE: Angiogenesis--inhibiting protein binding peptides and proteins and methods of use
INVENTOR(S): MacDonald, Nicholas J., Chevy Chase, MD, United States
Sim, Kim Lee, Gaithersburg, MD, United States
PATENT ASSIGNEE(S): EntreMed, Inc., Rockville, MD, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6201104	B1	20010313
APPLICATION INFO.:	US 1998-206059		19981204 (9)
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	Granted		
PRIMARY EXAMINER:	Mertz, Prema		
LEGAL REPRESENTATIVE:	Kilpatrick Stockton LLP		
NUMBER OF CLAIMS:	6		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	15 Drawing Figure(s); 7 Drawing Page(s)		
LINE COUNT:	1344		
CAS INDEXING IS AVAILABLE FOR THIS PATENT.			
AB	The present invention relates to peptides and proteins such as receptors that bind angiogenesis-related proteins ANGIOSTATIN.TM. protein or		

ENDOSTATIN.TM. protein. Peptides and proteins of the present invention can be isolated from body fluids including blood or urine, or can be synthesized by recombinant, enzymatic or chemical methods. The peptides are particularly important for identifying receptors of angiogenesis-related proteins, as well as for identifying other proteins that regulate, transport and otherwise interact with angiogenesis-related proteins.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

=> s angiogenesis
L7 97944 ANGIOGENESIS

=> s l7 (s) l2
L8 30 L7 (S) L2

=> duplicate remove l8
DUPLICATE PREFERENCE IS 'CAPLUS, EMBASE, BIOSIS, USPATFULL'
KEEP DUPLICATES FROM MORE THAN ONE FILE? Y/(N):n
PROCESSING COMPLETED FOR L8
L9 27 DUPLICATE REMOVE L8 (3 DUPLICATES REMOVED)

=> d l9 1- ibib,abs
YOU HAVE REQUESTED DATA FROM 27 ANSWERS - CONTINUE? Y/(N):y

L9 ANSWER 1 OF 27 CAPLUS COPYRIGHT 2003 ACS on STN DUPLICATE 1
ACCESSION NUMBER: 2003:174227 CAPLUS
DOCUMENT NUMBER: 138:216497
TITLE: Synthetic **zinc finger**
proteins and sequences bound by them and their
use in regulation of expression of the VEGF gene and
angiogenesis
INVENTOR(S): Rebar, Edward; Jamieson, Andrew; Liu, Qiang; Liu,
Pei-qi; Wolffe, Alan; Eisenberg, Stephen P.; Jarvis,
Eric
PATENT ASSIGNEE(S): USA
SOURCE: U.S. Pat. Appl. Publ., 75 pp., Cont.-in-part of U.S.
Ser. No. 736,083.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 3
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2003044404	A1	20030306	US 2001-846033	20010430
WO 2002046412	A2	20020613	WO 2001-US46861	20011206
WO 2002046412	A3	20030313		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, VZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
AU 2002028841	A5	20020618	AU 2002-28841	20011206
US 2003021776	A1	20030130	US 2001-6069	20011206
EP 1341914	A2	20030910	EP 2001-989961	20011206
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR			

PRIORITY APPLN. INFO.:

US 2000-733604 B2 20001207
US 2000-736083 B2 20001212
US 2001-846033 A 20010430
WO 2001-US46861 W 20011206

AB Synthetic C2H2 **zinc finger proteins** that bind to DNase I-hypersensitive sites in the vascular endothelial growth factor (VEGF) gene and that can be used to regulated gene expression and **angiogenesis** are described for use in treatment of ischemia, in wound healing, and other diseases assocd. with **angiogenesis**. The VEGF-A gene was analyzed to identify DNase I hypersensitive sites and an array of synthetic zinc finger domains fused to VP16 or NF-.kappa.B p65 were designed and tested for their ability to bind to constitutively and conditionally hypersensitive sites. Fusion products contg. 6 zinc fingers were shown to regulate transcription of the gene. When gene expression was induced by hypoxia, the pattern of splice variants from the gene was comparable found in control cells.

L9 ANSWER 2 OF 27 CAPLUS COPYRIGHT 2003 ACS on STN DUPLICATE 2

ACCESSION NUMBER: 2003:77320 CAPLUS

DOCUMENT NUMBER: 138:147722

TITLE: Chimeric **zinc finger proteins** for modulating vascular endothelial growth factor gene expression and therapeutic use in regulation of **angiogenesis**

INVENTOR(S): Rebar, Edward; Jamieson, Andrew; Liu, Qiang; Liu, Pei-Qi; Wolffe, Alan; Eisenberg, Stephen P.; Jarvis, Eric

PATENT ASSIGNEE(S): Sangamo Biosciences, Inc., USA

SOURCE: U.S. Pat. Appl. Publ., 120 pp., Cont.-in-part of U.S. Ser. No. 846,033.

CODEN: USXXCO

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 3

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2003021776	A1	20030130	US 2001-6069	20011206
US 2003044404	A1	20030306	US 2001-846033	20010430

PRIORITY APPLN. INFO.: US 2000-733604 B2 20001207
US 2000-736083 B2 20001212
US 2001-846033 A2 20010430

AB The invention provides methods and compns. for regulating angiogenesis, such methods and compns. being useful in a variety of applications where modulation of vascular formation is useful in treatments for ischemia and wound healing. Certain of the methods and compns. accomplish this by using various zinc finger proteins that bind to particular target sites in one or more VEGF genes. Nucleic acids encoding the zinc finger proteins are also disclosed. Methods for modulating the expression of one or more VEGF genes with the zinc finger proteins and nucleic acids are also disclosed. Such methods can also be utilized in a variety of therapeutic applications that involve the regulation of endothelial cell growth. Pharmaceutical compns. including the zinc finger proteins or nucleic acids encoding them are also provided.

L9 ANSWER 3 OF 27 USPATFULL on STN

ACCESSION NUMBER: 2003:258639 USPATFULL

TITLE: 207 human secreted proteins

INVENTOR(S): Ni, Jian, Germantown, MD, UNITED STATES
Ebner, Reinhard, Gaithersburg, MD, UNITED STATES
LaFleur, David W., Washington, DC, UNITED STATES
Moore, Paul A., Germantown, MD, UNITED STATES
Olsen, Henrik S., Gaithersburg, MD, UNITED STATES
Rosen, Craig A., Laytonsville, MD, UNITED STATES

Ruben, Steven M., Olney, MD, UNITED STATES
 Soppet, Daniel R., Centreville, VA, UNITED STATES
 Young, Paul E., Gaithersburg, MD, UNITED STATES
 Shi, Yanggu, Gaithersburg, MD, UNITED STATES
 Florence, Kimberly A., Rockville, MD, UNITED STATES
 Wei, Ying-Fei, Berkeley, CA, UNITED STATES
 Florence, Charles, Rockville, MD, UNITED STATES
 Hu, Jing-Shan, Mountain View, CA, UNITED STATES
 Li, Yi, Sunnyvale, CA, UNITED STATES
 Kyaw, Hla, Frederick, MD, UNITED STATES
 Fischer, Carrie L., Burke, VA, UNITED STATES
 Ferrie, Ann M., Painted Post, NY, UNITED STATES
 Fan, Ping, Potomac, MD, UNITED STATES
 Feng, Ping, Gaithersburg, MD, UNITED STATES
 Endress, Gregory A., Florence, MA, UNITED STATES
 Dillon, Patrick J., Carlsbad, CA, UNITED STATES
 Carter, Kenneth C., North Potomac, MD, UNITED STATES
 Brewer, Laurie A., St. Paul, MN, UNITED STATES
 Yu, Guo-Liang, Berkeley, CA, UNITED STATES
 Zeng, Zhizhen, Lansdale, PA, UNITED STATES
 Greene, John M., Gaithersburg, MD, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003181692	A1	20030925
APPLICATION INFO.:	US 2001-933767	A1	20010822 (9)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. WO 2001-US5614, filed on 21 Feb 2001, PENDING Continuation-in-part of Ser. No. US 1998-205258, filed on 4 Dec 1998, PENDING		

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-184836P	20000224 (60)
	US 2000-193170P	20000329 (60)
	US 1997-48885P	19970606 (60)
	US 1997-49375P	19970606 (60)
	US 1997-48881P	19970606 (60)
	US 1997-48880P	19970606 (60)
	US 1997-48896P	19970606 (60)
	US 1997-49020P	19970606 (60)
	US 1997-48876P	19970606 (60)
	US 1997-48895P	19970606 (60)
	US 1997-48884P	19970606 (60)
	US 1997-48894P	19970606 (60)
	US 1997-48971P	19970606 (60)
	US 1997-48964P	19970606 (60)
	US 1997-48882P	19970606 (60)
	US 1997-48899P	19970606 (60)
	US 1997-48893P	19970606 (60)
	US 1997-48900P	19970606 (60)
	US 1997-48901P	19970606 (60)
	US 1997-48892P	19970606 (60)
	US 1997-48915P	19970606 (60)
	US 1997-49019P	19970606 (60)
	US 1997-48970P	19970606 (60)
	US 1997-48972P	19970606 (60)
	US 1997-48916P	19970606 (60)
	US 1997-49373P	19970606 (60)
	US 1997-48875P	19970606 (60)
	US 1997-49374P	19970606 (60)
	US 1997-48917P	19970606 (60)
	US 1997-48949P	19970606 (60)
	US 1997-48974P	19970606 (60)
	US 1997-48883P	19970606 (60)
	US 1997-48897P	19970606 (60)

US 1997-48898P	19970606 (60)
US 1997-48962P	19970606 (60)
US 1997-48963P	19970606 (60)
US 1997-48877P	19970606 (60)
US 1997-48878P	19970606 (60)
US 1997-57645P	19970905 (60)
US 1997-57642P	19970905 (60)
US 1997-57668P	19970905 (60)
US 1997-57635P	19970905 (60)
US 1997-57627P	19970905 (60)
US 1997-57667P	19970905 (60)
US 1997-57666P	19970905 (60)
US 1997-57764P	19970905 (60)
US 1997-57643P	19970905 (60)
US 1997-57769P	19970905 (60)
US 1997-57763P	19970905 (60)
US 1997-57650P	19970905 (60)
US 1997-57584P	19970905 (60)
US 1997-57647P	19970905 (60)
US 1997-57661P	19970905 (60)
US 1997-57662P	19970905 (60)
US 1997-57646P	19970905 (60)
US 1997-57654P	19970905 (60)
US 1997-57651P	19970905 (60)
US 1997-57644P	19970905 (60)
US 1997-57765P	19970905 (60)
US 1997-57762P	19970905 (60)
US 1997-57775P	19970905 (60)
US 1997-57648P	19970905 (60)
US 1997-57774P	19970905 (60)
US 1997-57649P	19970905 (60)
US 1997-57770P	19970905 (60)
US 1997-57771P	19970905 (60)
US 1997-57761P	19970905 (60)
US 1997-57760P	19970905 (60)
US 1997-57776P	19970905 (60)
US 1997-57778P	19970905 (60)
US 1997-57629P	19970905 (60)
US 1997-57628P	19970905 (60)
US 1997-57777P	19970905 (60)
US 1997-57634P	19970905 (60)
US 1997-70923P	19971218 (60)
US 1998-92921P	19980715 (60)
US 1998-94657P	19980730 (60)
US 1997-70923P	19971218 (60)
US 1998-92921P	19980715 (60)
US 1998-94657P	19980730 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: HUMAN GENOME SCIENCES INC, 9410 KEY WEST AVENUE,
ROCKVILLE, MD, 20850

NUMBER OF CLAIMS: 23
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 10 Drawing Page(s)
LINE COUNT: 32746

AB The present invention relates to novel human secreted proteins and isolated nucleic acids containing the coding regions of the genes encoding such proteins. Also provided are vectors, host cells, antibodies, and recombinant methods for producing human secreted proteins. The invention further relates to diagnostic and therapeutic methods useful for diagnosing and treating diseases, disorders, and/or conditions related to these novel human secreted proteins.

ACCESSION NUMBER: 2003:244853 USPATFULL
TITLE: Albumin fusion proteins
INVENTOR(S): Rosen, Craig A., Laytonsville, MD, UNITED STATES
Sadeghi, Homayoun, Doylestown, PA, UNITED STATES
Prior, Christopher P., Rosemont, PA, UNITED STATES
Turner, Andrew J., Eagleville, PA, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003171267	A1	20030911
APPLICATION INFO.:	US 2001-833117	A1	20010412 (9)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-256931P	20001221 (60)
	US 2000-199384P	20000425 (60)
	US 2000-229358P	20000412 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: HUMAN GENOME SCIENCES INC, 9410 KEY WEST AVENUE,
ROCKVILLE, MD, 20850

NUMBER OF CLAIMS: 59
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 20 Drawing Page(s)
LINE COUNT: 13208

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention encompasses albumin fusion proteins. Nucleic acid molecules encoding the albumin fusion proteins of the invention are also encompassed by the invention, as are vectors containing these nucleic acids, host cells transformed with these nucleic acids vectors, and methods of making the albumin fusion proteins of the invention and using these nucleic acids, vectors, and/or host cells. Additionally the present invention encompasses pharmaceutical compositions comprising albumin fusion proteins and methods of treating, preventing, or ameliorating diseases, disorders or conditions using albumin fusion proteins of the invention.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 5 OF 27 USPATFULL on STN

ACCESSION NUMBER: 2003:237867 USPATFULL
TITLE: Human G-protein chemokine receptor (CCR5) HDGMR10
INVENTOR(S): Rosen, Craig A., Laytonsville, MD, UNITED STATES
Roschke, Viktor, Rockville, MD, UNITED STATES
Li, Yi, Sunnyvale, CA, UNITED STATES
Ruben, Steven M., Olney, MD, UNITED STATES
PATENT ASSIGNEE(S): Human Genome Sciences, Inc. (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003166024	A1	20030904
APPLICATION INFO.:	US 2002-135839	A1	20020501 (10)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 2001-779879, filed on 9 Feb 2001, ABANDONED		

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-181258P	20000209 (60)
	US 2000-187999P	20000309 (60)
	US 2000-234336P	20000922 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C., 1100 NEW
YORK AVENUE, N.W., SUITE 600, WASHINGTON, DC,
20005-3934

NUMBER OF CLAIMS: 61
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 4 Drawing Page(s)
LINE COUNT: 17941
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention relates to a novel human protein called Human G-protein Chemokine Receptor (CCR5) HDGNR10, and isolated polynucleotides encoding this protein. The invention is also directed to human antibodies that bind Human G-protein Chemokine Receptor (CCR5) HDGNR10 and to polynucleotides encoding those antibodies. Also provided are vectors, host cells, antibodies, and recombinant methods for producing Human G-protein Chemokine Receptor (CCR5) HDGNR10 and human anti-Human G-protein Chemokine Receptor (CCR5) HDGNR10 antibodies. The invention further relates to diagnostic and therapeutic methods useful for diagnosing and treating diseases, disorders, and/or conditions related to this novel human protein and these novel human antibodies.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 6 OF 27 USPATFULL on STN

ACCESSION NUMBER: 2003:220740 USPATFULL
TITLE: Methods and compositions for diagnosing and treating rheumatoid arthritis
INVENTOR(S): Pittman, Debra D., Windham, NH, UNITED STATES
Feldman, Jeffrey L., Arlington, MA, UNITED STATES
Shields, Kathleen M., Harvard, MA, UNITED STATES
Trepicchio, William L., Andover, MA, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003154032	A1	20030814
APPLICATION INFO.:	US 2001-23451	A1	20011217 (10)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-255861P	20001215 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	Patent Group, FOLEY, HOAG & ELIOT LLP, One Post Office Square, Boxton, MA, 02109	
NUMBER OF CLAIMS:	40	
EXEMPLARY CLAIM:	1	
LINE COUNT:	25385	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention provides methods and compositions for diagnostic assays for detecting R.A. and therapeutic methods and compositions for treating R.A. The invention also provides methods for designing, identifying, and optimizing therapeutics for R.A. Diagnostic compositions of the invention include compositions comprising detection agents for detecting one or more genes that have been shown to be up- or down-regulated in cells of R.A. relative to normal counterpart cells. Exemplary detection agents include nucleic acid probes, which can be in solution or attached to a solid surface, e.g., in the form of a microarray. The invention also provides computer-readable media comprising values of levels of expression of one or more genes that are up- or down-regulated in R.A.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 7 OF 27 USPATFULL on STN

ACCESSION NUMBER: 2003:219631 USPATFULL
TITLE: Full-length human cDNAs encoding potentially secreted proteins
INVENTOR(S): Dumas Milne Edwards, Jean-Baptiste, Paris, FRANCE
Bougueleret, Lydie, Petit Lancy, SWITZERLAND
Jobert, Severin, Paris, FRANCE

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003152921	A1	20030814
APPLICATION INFO.:	US 2001-876997	A1	20010608 (9)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 2000-731872, filed on 7 Dec 2000, PENDING		

	NUMBER	DATE
PRIORITY INFORMATION:	US 1999-169629P	19991208 (60)
	US 2000-187470P	20000306 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	Frank C. Eisenschenk, Ph.D., SALIWANCHIK, LLOYD & SALIWANCHIK, 2421 N.W. 41 STREET, SUITE A-1, GAINESVILLE, FL, 32606-6669	
NUMBER OF CLAIMS:	22	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	5 Drawing Page(s)	
LINE COUNT:	27600	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention concerns GENSET polynucleotides and polypeptides. Such GENSET products may be used as reagents in forensic analyses, as chromosome markers, as tissue/cell/organelle-specific markers, in the production of expression vectors. In addition, they may be used in screening and diagnosis assays for abnormal GENSET expression and/or biological activity and for screening compounds that may be used in the treatment of GENSET-related disorders.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 8 OF 27 USPATFULL on STN

ACCESSION NUMBER: 2003:206834 USPATFULL
 TITLE: Chemokine beta-1 fusion proteins
 INVENTOR(S): Bell, Adam, Germantown, MD, UNITED STATES
 Ruben, Steven M., Olney, MD, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003143191	A1	20030731
APPLICATION INFO.:	US 2002-153604	A1	20020524 (10)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2001-293212P	20010525 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	HUMAN GENOME SCIENCES INC, 9410 KEY WEST AVENUE, ROCKVILLE, MD, 20850	
NUMBER OF CLAIMS:	17	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	21 Drawing Page(s)	
LINE COUNT:	15446	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention relates to novel chemokine polypeptides and encoding nucleic acids. More specifically, therapeutic compositions and methods are provided using isolated nucleic acid molecules encoding a human chemokine beta-1 (Ck.beta.-1 or Ckb1) polypeptide (previously termed monocyte-colony inhibitory factor (M-CIF), MIP1-.gamma., and Hemofiltrate CC chemokine-1 (HCC-1)), and Ckb1 polypeptides themselves, as are vectors, host cells and recombinant methods for producing the same. Also provided are methods of treating, preventing, ameliorating diseases using such compounds.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 9 OF 27 USPATFULL on STN

ACCESSION NUMBER: 2003:200905 USPATFULL

TITLE: Novel G protein-coupled receptor family members, human thioredoxin family members, human leucine-rich repeat family members, and human ringfinger family member

INVENTOR(S): Glucksmann, Maria Alexandra, Lexington, MA, UNITED STATES
Silos-Santiago, Inmaculada, Jamaica Plain, MA, UNITED STATES
Galvin, Katherine M., Jamaica Plain, MA, UNITED STATES
Weich, Nadine, Brookline, MA, UNITED STATES
Curtis, Rory A. J., Framingham, MA, UNITED STATES
Bandaru, Rajasekhar, Watertown, MA, UNITED STATES
Kapeller-Libermann, Rosana, Chestnut Hill, MA, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003138890	A1	20030724
APPLICATION INFO.:	US 2002-145586	A1	20020514 (10)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 2001-796338, filed on 28 Feb 2001; PENDING Continuation-in-part of Ser. No. WO 2001-US6543, filed on 28 Feb 2001, PENDING		

	NUMBER	DATE
PRIORITY INFORMATION:	WO 2001-US6057	20010223
	WO 2001-US23152	20010723
	WO 2001-US40476	20010409
	WO 2001-US7139	20010305
	WO 2001-US19544	20010615
	WO 2001-US29967	20010925
	WO 2001-US9470	20010323
	WO 2001-US10380	20010330
	WO 2001-US29968	20010925
	US 2000-186059P	20000229 (60)
	US 2000-220042P	20000721 (60)
	US 2000-187447P	20000307 (60)
	US 2000-211673P	20000615 (60)
	US 2000-235049P	20000925 (60)
	US 2000-191863P	20000324 (60)
	US 2000-193919P	20000331 (60)
	US 2000-235032P	20000925 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: JOHN W. FREEMAN, ESQ., Fish & Richardson P.C., 225 Franklin Street, Boston, MA, 02110-2804

NUMBER OF CLAIMS: 19
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 97 Drawing Page(s)
LINE COUNT: 51652

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention provides isolated nucleic acids molecules, designated 20716, 65494, 44576, 1983, 52881, 2398, 45449, 50289, 52872, 22105, 22109, 22108, 47916, 33395, 31939, and 84241 nucleic acid molecules, which encode novel G protein-coupled receptor family members, human thioredoxin family members, human leucine-rich repeat family members, and human ringfinger family member. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing 20716, 65494, 44576, 1983, 52881, 2398, 45449, 50289, 52872, 22105, 22109, 22108, 47916, 33395, 31939, or 84241 nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a 20716, 65494,

44576, 1983, 52881, 2398, 45449, 50289, 52872, 22105, 22109, 22108, 47916, 33395, 31939, or 84241 gene has been introduced or disrupted. The invention still further provides isolated 20716, 65494, 44576, 1983, 52881, 2398, 45449, 50289, 52872, 22105, 22109, 22108, 47916, 33395, 31939, or 84241 proteins, fusion proteins, antigenic peptides and anti-20716, 65494, 44576, 1983, 52881, 2398, 45449, 50289, 52872, 22105, 22109, 22108, 47916, 33395, 31939, or 84241 antibodies. Diagnostic methods utilizing compositions of the invention are also provided.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 10 OF 27 USPATFULL on STN

ACCESSION NUMBER: 2003:181414 USPATFULL
 TITLE: Albumin fusion proteins
 INVENTOR(S): Rosen, Craig A., Laytonsville, MD, UNITED STATES
 Haseltine, William A., Washington, DC, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003125247	A1	20030703
APPLICATION INFO.:	US 2001-833041	A1	20010412 (9)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-256931P	20001221 (60)
	US 2000-199384P	20000425 (60)
	US 2000-229358P	20000412 (60)

DOCUMENT TYPE: Utility
 FILE SEGMENT: APPLICATION
 LEGAL REPRESENTATIVE: HUMAN GENOME SCIENCES INC, 9410 KEY WEST AVENUE, ROCKVILLE, MD, 20850

NUMBER OF CLAIMS: 29
 EXEMPLARY CLAIM: 1
 NUMBER OF DRAWINGS: 20 Drawing Page(s)
 LINE COUNT: 15235

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention encompasses albumin fusion proteins. Nucleic acid molecules encoding the albumin fusion proteins of the invention are also encompassed by the invention, as are vectors containing these nucleic acids, host cells transformed with these nucleic acids vectors, and methods of making the albumin fusion proteins of the invention and using these nucleic acids, vectors, and/or host cells. Additionally the present invention encompasses pharmaceutical compositions comprising albumin fusion proteins and methods of treating, preventing, or ameliorating diseases, disorders or conditions using albumin fusion proteins of the invention.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 11 OF 27 USPATFULL on STN

ACCESSION NUMBER: 2003:180711 USPATFULL
 TITLE: Interventions to mimic the effects of calorie restriction
 INVENTOR(S): Spindler, Stephen R., Riverside, CA, UNITED STATES
 PATENT ASSIGNEE(S): The Regents of the University of California (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003124540	A1	20030703
APPLICATION INFO.:	US 2002-56749	A1	20020122 (10)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 2000-648642, filed on 25 Aug 2000, GRANTED, Pat. No. US 6406853		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	APPLICATION		

LEGAL REPRESENTATIVE: TOWNSEND AND TOWNSEND AND CREW, LLP, TWO EMBARCADERO
CENTER, EIGHTH FLOOR, SAN FRANCISCO, CA, 94111-3834
NUMBER OF CLAIMS: 28
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 13 Drawing Page(s)
LINE COUNT: 2446

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Long term calorie restriction has the benefit of increasing life span. Methods to screen interventions that mimic the effects of calorie restriction are disclosed. Extensive analysis of genes for which expression is statistically different between control and calorie restricted animals has demonstrated that specific genes are preferentially expressed during calorie restriction. Screening for interventions which produce the same expression profile will provide interventions that increase life span. In a further aspect, it has been discovered that test animals on a calorie restricted diet for a relatively short time have a similar gene expression profile to test animals which have been on a long term calorie restricted diet.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 12 OF 27 USPATFULL on STN

ACCESSION NUMBER: 2003:146312 USPATFULL
TITLE: Human G-protein Chemokine Receptor (CCR5) HDGNR10
INVENTOR(S): Roschke, Viktor, Rockville, MD, UNITED STATES
Rosen, Craig A., Laytonsville, MD, UNITED STATES
Ruben, Steven M., Olney, MD, UNITED STATES
PATENT ASSIGNEE(S): Human Genome Sciences, Inc. (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003100058	A1	20030529
APPLICATION INFO.:	US 2002-67800	A1	20020208 (10)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. WO 2001-US4153, filed on 9 Feb 2001, UNKNOWN Continuation-in-part of Ser. No. US 2001-779880, filed on 9 Feb 2001, PENDING		

	NUMBER	DATE
PRIORITY INFORMATION:	US 2001-297257P	20010612 (60)
	US 2001-310458P	20010808 (60)
	US 2001-328447P	20011012 (60)
	US 2001-341725P	20011221 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C., 1100 NEW YORK AVENUE, N.W., SUITE 600, WASHINGTON, DC, 20005-3934	
NUMBER OF CLAIMS:	60	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	7 Drawing Page(s)	
LINE COUNT:	18955	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention relates to a novel human protein called Human G-protein Chemokine Receptor (CCR5) HDGNR10, and isolated polynucleotides encoding this protein. The invention is also directed to human antibodies that bind Human G-protein Chemokine Receptor (CCR5) HDGNR10 and to polynucleotides encoding those antibodies. Also provided are vectors, host cells, antibodies, and recombinant methods for producing Human G-protein Chemokine Receptor (CCR5) HDGNR10 and human anti-Human G-protein Chemokine Receptor (CCR5) HDGNR10 antibodies. The invention further relates to diagnostic and therapeutic methods useful for diagnosing and treating diseases, disorders, and/or conditions related to this novel human protein and these novel human antibodies.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 13 OF 27 USPATFULL on STN

ACCESSION NUMBER: 2003:141109 USPATFULL
TITLE: SECRETED PROTEINS AND POLYNUCLEOTIDES ENCODING THEM
INVENTOR(S): JACOBS, KENNETH, NEWTON, MA, UNITED STATES
MCCOY, JOHN M., READING, MA, UNITED STATES
LAVALLIE, EDWARD R., HARVARD, MA, UNITED STATES
COLLINS-RACIE, LISA A., ACTON, MA, UNITED STATES
MERBERG, DAVID, ACTON, MA, UNITED STATES
AGOSTINO, MICHAEL J., ANDOVER, MA, UNITED STATES
STEININGER, ROBERT, II, CAMBRIDGE, MA, UNITED STATES
SPAULDING, VIKKI, BILLERICA, MA, UNITED STATES
WONG, GORDON G., BROOKLINE, MA, UNITED STATES
CLARK, HILARY F., SAN FRANCISCO, CA, UNITED STATES
FECHTEL, KIM, ARLINGTON, MA, UNITED STATES
EVANS, CHERYL, GERMANTOWN, MD, UNITED STATES
TREACY, MAURICE, DUBLIN, IRELAND

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003096951	A1	20030522
APPLICATION INFO.:	US 1999-374046	A1	19990813 (9)

	NUMBER	DATE
PRIORITY INFORMATION:	US 1998-96622P	19980814 (60)
	US 1998-96815P	19980817 (60)
	US 1998-99229P	19980904 (60)
	US 1998-105368P	19981023 (60)
	US 1999-115234P	19990108 (60)
	US 1999-119931P	19990212 (60)
	US 1999-120575P	19990218 (60)
	US 1999-132020P	19990430 (60)
	US 1999-148424P	19990811 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: LAHIVE & COCKFIELD, 28 STATE STREET, BOSTON, MA, 02109
NUMBER OF CLAIMS: 13
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 3 Drawing Page(s)
LINE COUNT: 22385

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Novel polynucleotides and the proteins encoded thereby are disclosed.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 14 OF 27 USPATFULL on STN

ACCESSION NUMBER: 2003:203218 USPATFULL
TITLE: Functional genomics using zinc finger proteins
INVENTOR(S): Case, Casey C., San Mateo, CA, United States
Zhang, Lei, San Francisco, CA, United States
PATENT ASSIGNEE(S): Sangamo BioScience, Inc., Richmond, CA, United States
(U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6599692	B1	20030729
APPLICATION INFO.:	US 1999-395448		19990914 (9)
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	GRANTED		
PRIMARY EXAMINER:	Brusca, John S.		
LEGAL REPRESENTATIVE:	Robins & Pasternak LLP		
NUMBER OF CLAIMS:	55		
EXEMPLARY CLAIM:	1		

NUMBER OF DRAWINGS: 5 Drawing Figure(s); 5 Drawing Page(s)

LINE COUNT: 3576

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention provides methods of regulating gene expression using recombinant zinc finger proteins, for functional genomics and target validation applications.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 15 OF 27 CAPLUS COPYRIGHT 2003 ACS on STN

ACCESSION NUMBER: 2002:449871 CAPLUS

DOCUMENT NUMBER: 137:29656

TITLE: Selection of **zinc finger protein** targeting sites in VEGF gene promoter region and methods of designing **zinc finger proteins** to bind to preselected sites for modulation of **angiogenesis**

INVENTOR(S): Rebar, Edward; Jamieson, Andrew; Liu, Qiang; Liu, Pei-Qi; Wolffe, Alan; Eisenberg, Stephen P.; Jarvis, Eric

PATENT ASSIGNEE(S): Sangamo Biosciences, Inc., USA

SOURCE: PCT Int. Appl., 195 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 3

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002046412	A2	20020613	WO 2001-US46861	20011206
WO 2002046412	A3	20030313		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
US 2003044404	A1	20030306	US 2001-846033	20010430
AU 2002028841	A5	20020618	AU 2002-28841	20011206
EP 1341914	A2	20030910	EP 2001-989961	20011206
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR			
PRIORITY APPLN. INFO.:			US 2000-733604	A 20001207
			US 2000-736083	A 20001212
			US 2001-846033	A 20010430
			WO 2001-US46861	W 20011206

AB The invention provides criteria and methods for selecting optimum subsequence(s) from the promoter region of animal vascular endothelial growth factor (VEGF) gene for targeting by a zinc finger protein. The invention also provides methods of designing zinc finger protein segments (seven contiguous amino acids) that bind to a preselected target site. The targeting sequences in the promoter region of VEGF and the sequences of segment of zinc finger proteins were disclosed. The expression of zinc finger protein segments stimulated the expression of VEGF in human, mouse and rat cells. The ZFP provides in this invention can be used to modulate the expression of VEGF for treatment of diseases such as atherosclerosis, ischemia, arthritis, injury and tumors.

L9 ANSWER 16 OF 27 USPATFULL on STN

ACCESSION NUMBER: 2002:294532 USPATFULL
TITLE: Gene identification
INVENTOR(S): Case, Casey C., San Mateo, CA, UNITED STATES
Urnov, Fyodor, Richmond, CA, UNITED STATES
PATENT ASSIGNEE(S): Sangamo BioSciences, Inc., a Delaware Corporation,
Richmond, CA (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2002164575	A1	20021107
APPLICATION INFO.:	US 2001-942090	A1	20010828 (9)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 1999-395448, filed on 14 Sep 1999, PENDING		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	APPLICATION		
LEGAL REPRESENTATIVE:	ROBINS & PASTERNAK LLP, 545 MIDDLEFIELD ROAD, SUITE 180, MENLO PARK, CA, 94025		
NUMBER OF CLAIMS:	30		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	5 Drawing Page(s)		
LINE COUNT:	3687		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present disclosure provides methods and compositions for identifying a particular genomic sequence as a gene and/or a coding region, once that sequence has been tentatively identified as a gene based on genomic analysis using one or more gene prediction algorithms. The methods include the use of exogenous molecules such as zinc finger proteins which are capable of binding to and modulating expression of gene transcription, targeted to putative gene sequences, followed by assay for one or more selected phenotypes.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 17 OF 27 USPATFULL on STN

ACCESSION NUMBER: 2002:191539 USPATFULL
TITLE: Full-length human cDNAs encoding potentially secreted proteins
INVENTOR(S): Milne Edwards, Jean-Baptiste Dumas, Paris, FRANCE
Bougueleret, Lydie, Petit Lancy, SWITZERLAND
Jobert, Severin, Paris, FRANCE

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2002102604	A1	20020801
APPLICATION INFO.:	US 2000-731872	A1	20001207 (9)

	NUMBER	DATE
PRIORITY INFORMATION:	US 1999-169629P	19991208 (60)
	US 2000-187470P	20000306 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	John Lucas, Ph.D., J.D., Genset Corporation, 10665 Srrrento Valley Road, San Diego, CA, 92121-1609	
NUMBER OF CLAIMS:	29	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	5 Drawing Page(s)	
LINE COUNT:	28061	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention concerns GENSET polynucleotides and polypeptides. Such GENSET products may be used as reagents in forensic analyses, as chromosome markers, as tissue/cell/organelle-specific markers, in the production of expression vectors. In addition, they may be used in screening and diagnosis assays for abnormal GENSET expression and/or biological activity and for screening compounds that may be used in the

treatment of GENSET-related disorders.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 18 OF 27 USPATFULL on STN

ACCESSION NUMBER: 2002:178741 USPATFULL
TITLE: Gene identification
INVENTOR(S): Case, Casey C., San Mateo, CA, UNITED STATES
Urnov, Fyodor, Richmond, CA, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2002094529	A1	20020718
APPLICATION INFO.:	US 2001-941450	A1	20010828 (9)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 1999-395448, filed on 14 Sep 1999, PENDING		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	APPLICATION		
LEGAL REPRESENTATIVE:	ROBINS & PASTERNAK LLP, 90 MIDDLEFIELD ROAD, SUITE 200, MENLO PARK, CA, 94025		
NUMBER OF CLAIMS:	30		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	5 Drawing Page(s)		
LINE COUNT:	3838		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present disclosure provides methods and compositions for identifying a particular genomic sequence as a gene and/or a coding region, once that sequence has been tentatively identified as a gene based on genomic analysis using one or more gene prediction algorithms. The methods include the use of exogenous molecules such as zinc finger proteins which are capable of binding to and modulating expression of gene transcription, targeted to putative gene sequences, followed by assay for one or more selected phenotypes.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 19 OF 27 USPATFULL on STN

ACCESSION NUMBER: 2002:157015 USPATFULL
TITLE: Functional genomics using zinc finger proteins
INVENTOR(S): Case, Casey C., San Mateo, CA, UNITED STATES
Zhang, Lei, San Francisco, CA, UNITED STATES
PATENT ASSIGNEE(S): Sangamo BioSciences, Inc. (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2002081614	A1	20020627
APPLICATION INFO.:	US 2001-925796	A1	20010809 (9)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 1999-395448, filed on 14 Sep 1999, PENDING		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	APPLICATION		
LEGAL REPRESENTATIVE:	ROBINS & PASTERNAK LLP, Suite 200, 90 Middlefield Road, Menlo Park, CA, 94025		
NUMBER OF CLAIMS:	86		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	5 Drawing Page(s)		
LINE COUNT:	3297		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB 0 The present invention provides methods of regulating gene expression using recombinant zinc finger proteins, for functional genomics and target validation applications.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 20 OF 27 USPATFULL on STN

ACCESSION NUMBER: 2002:119846 USPATFULL
TITLE: Human G-protein Chemokine receptor (CCR5) HDGNR10
INVENTOR(S): Rosen, Craig A., Laytonsville, MD, UNITED STATES
Roschke, Viktor, Rockville, MD, UNITED STATES
Li, Yi, Sunnyvale, CA, UNITED STATES
Ruben, Steven M., Olney, MD, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2002061834	A1	20020523
APPLICATION INFO.:	US 2001-779880	A1	20010209 (9)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-181258P	20000209 (60)
	US 2000-187999P	20000309 (60)
	US 2000-234336P	20000922 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	STERNE, KESSLER, GOLDSTEIN & FOX PLLC, 1100 NEW YORK AVENUE, N.W., SUITE 600, WASHINGTON, DC, 20005-3934	
NUMBER OF CLAIMS:	61	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	4 Drawing Page(s)	
LINE COUNT:	18667	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention relates to a novel human protein called Human G-protein Chemokine Receptor (CCR5) HDGNR10, and isolated polynucleotides encoding this protein. The invention is also directed to human antibodies that bind Human G-protein Chemokine Receptor (CCR5) HDGNR10 and to polynucleotides encoding those antibodies. Also provided are vectors, host cells, antibodies, and recombinant methods for producing Human G-protein Chemokine Receptor (CCR5) HDGNR10 and human anti-Human G-protein Chemokine Receptor (CCR5) HDGNR10 antibodies. The invention further relates to diagnostic and therapeutic methods useful for diagnosing and treating diseases, disorders, and/or conditions related to this novel human protein and these novel human antibodies.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 21 OF 27 USPATFULL on STN

ACCESSION NUMBER: 2002:92268 USPATFULL
TITLE: Human G-protein Chemokine Receptor HDGNR10
INVENTOR(S): Rosen, Craig A., Laytonsville, MD, UNITED STATES
Roschke, Viktor, Rockville, MD, UNITED STATES
Li, Yi, Sunnyvale, CA, UNITED STATES
Ruben, Steven M., Olney, MD, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2002048786	A1	20020425
APPLICATION INFO.:	US 2001-779879	A1	20010209 (9)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-181258P	20000209 (60)
	US 2000-187999P	20000309 (60)
	US 2000-234336P	20000922 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	STERNE, KESSLER, GOLDSTEIN & FOX PLLC, 1100 NEW YORK AVENUE, N.W., SUITE 600, WASHINGTON, DC, 20005-3934	
NUMBER OF CLAIMS:	61	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	4 Drawing Page(s)	

LINE COUNT: 17969

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention relates to a novel human protein called Human G-protein Chemokine Receptor (CCR5) HDGNR10, and isolated polynucleotides encoding this protein. The invention is also directed to human antibodies that bind Human G-protein Chemokine Receptor (CCR5) HDGNR10 and to polynucleotides encoding those antibodies. Also provided are vectors, host cells, antibodies, and recombinant methods for producing Human G-protein Chemokine Receptor (CCR5) HDGNR10 and human anti-Human G-protein Chemokine Receptor (CCR5) HDGNR10 antibodies. The invention further relates to diagnostic and therapeutic methods useful for diagnosing and treating diseases, disorders, and/or conditions related to this novel human protein and these novel human antibodies.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 22 OF 27 USPATFULL on STN

ACCESSION NUMBER: 2002:144075 USPATFULL

TITLE: Interventions to mimic the effects of calorie restriction

INVENTOR(S): Spindler, Stephen R., Riverside, CA, United States

PATENT ASSIGNEE(S): The Regents of the University of California, Oakland, CA, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6406853	B1	20020618
APPLICATION INFO.:	US 2000-648642		20000825 (9)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 1999-471225, filed on 23 Dec 1999		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	GRANTED		
PRIMARY EXAMINER:	Jones, W. Gary		
ASSISTANT EXAMINER:	Taylor, Janell E.		
LEGAL REPRESENTATIVE:	Townsend & Townsend & Crew LLP		
NUMBER OF CLAIMS:	26		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	13 Drawing Figure(s); 13 Drawing Page(s)		
LINE COUNT:	2230		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Long term calorie restriction has the benefit of increasing life span. Methods to screen interventions that mimic the effects of calorie restriction are disclosed. Extensive analysis of genes for which expression is statistically different between control and calorie restricted animals has demonstrated that specific genes are preferentially expressed during calorie restriction. Screening for interventions which produce the same expression profile will provide interventions that increase life span. In a further aspect, it has been discovered that test animals on a calorie restricted diet for a relatively short time have a similar gene expression profile to test animals which have been on a long term calorie restricted diet.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 23 OF 27 USPATFULL on STN

ACCESSION NUMBER: 2002:137019 USPATFULL

TITLE: Agent and method for controlling angiogenesis

INVENTOR(S): Fernandez-Pol, Jose A., Chesterfield, MO, United States

PATENT ASSIGNEE(S): Novactyl, Inc., St. Louis, MO, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6403618	B1	20020611
APPLICATION INFO.:	US 2000-677506		20001002 (9)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-182608P	20000215 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	GRANTED	
PRIMARY EXAMINER:	Rotman, Alan L.	
ASSISTANT EXAMINER:	Robinson, Binta	
LEGAL REPRESENTATIVE:	Amos, Ahaji Kirk	
NUMBER OF CLAIMS:	3	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	19 Drawing Figure(s); 13 Drawing Page(s)	
LINE COUNT:	1620	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB A metal ion chelating agent such as picolinic acid or derivatives thereof, and methods of using the same. The agents chelate metals in metal containing protein complexes and enzymes required for growth and replication of blood vessel cells. The preparations can be administered systemically or for topical use. The preparations have antineoplastic activity augmented by the antiangiogenic properties.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 24 OF 27 EMBASE COPYRIGHT 2003 ELSEVIER INC. ALL RIGHTS RESERVED.
on STN DUPLICATE 3

ACCESSION NUMBER: 2003007246 EMBASE
TITLE: Induction of angiogenesis in a mouse model using engineered transcription factors.
AUTHOR: Rebar E.J.; Huang Y.; Hickey R.; Nath A.K.; Meoli D.; Nath S.; Chen B.; Xu L.; Liang Y.; Jamieson A.C.; Zhang L.; Spratt S.K.; Case C.C.; Wolffe A.; Giordano F.J.
CORPORATE SOURCE: F.J. Giordano, Dept. of Medicine, Yale University School of Medicine, New Haven, CT, United States.
fjgg@email.med.yale.edu
SOURCE: Nature Medicine, (1 Dec 2002) 8/12 (1427-1432).
Refs: 22
ISSN: 1078-8956 CODEN: NAMEFI
COUNTRY: United States
DOCUMENT TYPE: Journal; Article
FILE SEGMENT: 029 Clinical Biochemistry
LANGUAGE: English
SUMMARY LANGUAGE: English

AB The relationship between the structure of **zinc-finger protein** (ZFP) transcription factors and DNA sequence binding specificity has been extensively studied. Advances in this field have made it possible to design ZFPs de novo that will bind to specific targeted DNA sequences(2-10). It has been proposed that such designed ZFPs may eventually be useful in gene therapy(6,7,10). A principal advantage of this approach is that activation of an endogenous gene ensures expression of the natural array of splice variants(2). Preliminary studies in tissue culture have validated the feasibility of this approach(2-4). The studies reported here were intended to test whether engineered transcription factors are effective in a whole-organism model. ZFPs were designed to regulate the endogenous gene encoding vascular endothelial growth factor-A (Vegfa). Expression of these new ZFPs in vivo led to induced expression of the protein VEGF-A, stimulation of **angiogenesis** and acceleration of experimental wound healing. In addition, the neovasculature resulting from ZFP-induced expression of Vegfa was not hyperpermeable as was that produced by expression of murine Vegfa(164) cDNA. These data establish, for the first time, that specifically designed transcription factors can regulate an endogenous gene in vivo and evoke a potentially therapeutic biophysiologic effect.

L9 ANSWER 25 OF 27 CAPLUS COPYRIGHT 2003 ACS on STN
ACCESSION NUMBER: 2001:598291 CAPLUS

DOCUMENT NUMBER: 135:175339
 TITLE: Cells for drug discovery
 INVENTOR(S): Case, Casey
 PATENT ASSIGNEE(S): Sangamo Biosciences, Inc., USA
 SOURCE: PCT Int. Appl., 99 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001059450	A2	20010816	WO 2001-US4301	20010208
WO 2001059450	A3	20020502		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
US 2002045158	A1	20020418	US 2001-779233	20010208
EP 1254369	A2	20021106	EP 2001-924089	20010208
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
JP 2003180386	A2	20030702	JP 2002-311841	20010208
JP 2003522536	T2	20030729	JP 2001-558729	20010208
US 2003175790	A1	20030918	US 2003-412105	20030410
US 2003180713	A1	20030925	US 2003-412109	20030410
PRIORITY APPLN. INFO.:				
			US 2000-181117P	P 20000208
			JP 2001-558729	A3 20010208
			US 2001-779233	A3 20010208
			WO 2001-US4301	W 20010208

AB Disclosed herein are compns. and method useful in screening a compd. for its interaction and/or effect with a mol. target and/or cellular process.

L9 ANSWER 26 OF 27 CAPLUS COPYRIGHT 2003 ACS on STN

ACCESSION NUMBER: 2001:465883 CAPLUS
 DOCUMENT NUMBER: 135:208996
 TITLE: Molecular profiling of transformed and metastatic murine squamous carcinoma cells by differential display and cDNA microarray reveals altered expression of multiple genes related to growth, apoptosis, angiogenesis, and the NF- κ B signal pathway
 AUTHOR(S): Dong, Gang; Loukinova, Elena; Chen, Zhong; Gangi, Lisa; Chanturita, Tatyana I.; Liu, Edison T.; Van Waes, Carter
 CORPORATE SOURCE: Head and Neck Surgery Branch; National Institute on Deafness and Other Communication Disorders/NIH, Bethesda, MD, 20892, USA
 SOURCE: Cancer Research (2001), 61(12), 4797-4808
 CODEN: CNREA8; ISSN: 0008-5472
 PUBLISHER: American Association for Cancer Research
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 AB To identify changes in gene expression with transformation and metastasis, we investigated differential gene expression in a squamous carcinoma model established in syngeneic mice. We used mRNA differential display (DD) to detect global differences and cDNA arrays enriched for cancer-assocd. genes using mRNA from primary keratinocytes, transformed Pam 212 squamous carcinoma cells, and metastases of Pam 212. After DD, 72 candidate cDNAs expressed primarily in transformed and metastatic cells were selected and

cloned. Fifty-seven were detected, and 32 were confirmed to be differentially expressed by Northern blot anal. MRNA expression profiles were also generated using a mouse cDNA array composed of 4000 elements representing known genes and expressed sequence tags plus the 57 DD candidate cDNAs detected by Northern anal. to facilitate data validation. CDNA array detected 76.9% of the differentially expressed mRNAs selected from DD and confirmed by Northern blot, whereas low-abundance mRNAs did not reach the threshold for detection by the lower-sensitivity array method. Clustering anal. of DD and array results from transformed and metastatic cells identified genes that exhibited decreased or increased expression with transformation and metastasis. Alterations in the expression of several genes detected during tumor progression were consistent with their functional activities involving growth (p21, p27, and cyclin D1), resistance and apoptosis (glutathione-S-transferase, cIAP-1, PEA-15, and Fas ligand), inflammation and angiogenesis [chemokine growth-regulated oncogene 1 (also called KC)], and signal transduction (c-Met, yes-assocd. protein, and syk). Strikingly, 10 of 22 genes in the cluster expressed in metastases have been assocd. with activation of the nuclear factor (NF)-.kappa.B signal pathway. The NF-.kappa.B-inducible cytokine Gro-1 was recently shown to promote tumor growth, metastasis, and angiogenesis of squamous cell carcinomas in vivo. The results demonstrate that early response genes related to NF-.kappa.B contribute to metastatic tumor progression. Comparison of cell lines and tumor tissue revealed a concordance of .apprx.50% by array, and 70% for Northern-confirmed, metastasis-related genes. Functional genomic approaches comparing expression among cell lines and tumor tissue may promote a better understanding of the genes expressed by malignant and host cells during tumor progression and metastasis.

REFERENCE COUNT: 87 THERE ARE 87 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L9 ANSWER 27 OF 27 CAPLUS COPYRIGHT 2003 ACS on STN

ACCESSION NUMBER: 1998:1578 CAPLUS

DOCUMENT NUMBER: 128:84756

TITLE: The zinc finger protein ZPR1 binding to non-activated proteins and its functions as a second messenger

INVENTOR(S): Davis, Roger J.; Galcheva-Gargova, Zoya

PATENT ASSIGNEE(S): University of Massachusetts, USA

SOURCE: PCT Int. Appl., 88 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9746684	A1	19971211	WO 1997-US9911	19970606
W: AU, CA, JP, KR				
RW: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
AU 9733051	A1	19980105	AU 1997-33051	19970606
US 5925566	A	19990720	US 1997-870518	19970606
PRIORITY APPLN. INFO.:			US 1996-19219P	P 19960606
			WO 1997-US9911	W 19970606

AB The ZPR1 protein, a zinc finger protein, binds to a no. of receptor that have not been activated by ligand binding. When the receptor binds its ligand the ZPR1 protein is released to diffuse to other sites, notably the nucleus, to initiate ligand-induced responses. ZPR1 binds small nucleolar RNAs, such as U3. ZPR1 proteins of mammals (human and mouse) and yeasts (Saccharomyces cerevisiae and Schizosaccharomyces pombe) and the genes encoding them are cloned and characterized. Therapeutic uses of the ZPR1 protein are discussed.

=> log y

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

96.58

97.00

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)

SINCE FILE

TOTAL

ENTRY

SESSION

CA SUBSCRIBER PRICE

-3.91

-3.91

STN INTERNATIONAL LOGOFF AT 17:27:27 ON 16 OCT 2003